Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1398

1.

PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study.

Kim H, Kwon HJ, Park SY, Park E, Chung JH.

Oncotarget. 2017 Oct 6;8(58):98524-98532. doi: 10.18632/oncotarget.21567. eCollection 2017 Nov 17.

2.

Altered follicular helper T cell impaired antibody production in a murine model of myelodysplastic syndromes.

Jiang H, Cui N, Yang L, Liu C, Yue L, Guo L, Wang H, Shao Z.

Oncotarget. 2017 Oct 6;8(58):98270-98279. doi: 10.18632/oncotarget.21548. eCollection 2017 Nov 17.

3.

Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma in situ and minimally invasive adenocarcinoma of lung.

Yu R, He Z, Lou Y, Jiang H, Wu Y, Liu Z, Pan H, Han W.

Oncotarget. 2017 Oct 26;8(58):97801-97810. doi: 10.18632/oncotarget.22082. eCollection 2017 Nov 17.

4.

Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer.

Guan Y, Zhang R, Peng Z, Dong D, Wei G, Wang Y.

J Bone Oncol. 2017 Nov 1;9:59-64. doi: 10.1016/j.jbo.2017.10.002. eCollection 2017 Nov.

5.

Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model.

Du Y, Sun T, Liang X, Li Y, Jin Z, Xue H, Wan Y, Tian J.

Int J Nanomedicine. 2017 Nov 21;12:8337-8351. doi: 10.2147/IJN.S149235. eCollection 2017.

6.

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.

Liu B, Song Y, Liu D.

J Hematol Oncol. 2017 Dec 1;10(1):174. doi: 10.1186/s13045-017-0541-9. Review.

7.

Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis.

Zhang X, Fang C, Zhang G, Jiang F, Wang L, Hou J.

Oncotarget. 2017 Sep 21;8(54):93156-93167. doi: 10.18632/oncotarget.21114. eCollection 2017 Nov 3.

8.

Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer.

Cui S, Su X, Dong L, Qian J, Ye L, Zhang T, Fu H, Han H, Huang J, Yao Y, Gu Y, Jiang L.

J Cancer. 2017 Oct 24;8(19):4075-4082. doi: 10.7150/jca.21415. eCollection 2017.

9.

Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer.

Tartarone A, Lerose R, Rodriquenz MG, Mambella G, Calderoni G, Bozza G, Aieta M.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1359-S1363. doi: 10.21037/jtd.2017.07.80. Review.

10.

Optimizing peptide epitope-based autoantibody detection in cancer patients.

Wang M, Lomeli SH, Franklin WA, Lee S, Pantuck AJ, Zeng G.

Am J Clin Exp Immunol. 2017 Nov 1;6(5):84-91. eCollection 2017.

11.

Immune checkpoints, their control by immunotherapy and ovarian cancer.

Bose CK.

Contemp Oncol (Pozn). 2017;21(3):189-196. doi: 10.5114/wo.2017.70108. Epub 2017 Sep 29. Review.

12.

Management of intracranial melanomas in the era of precision medicine.

Young GJ, Bi WL, Wu WW, Johanns TM, Dunn GP, Dunn IF.

Oncotarget. 2017 Jul 13;8(51):89326-89347. doi: 10.18632/oncotarget.19223. eCollection 2017 Oct 24. Review.

13.

A Bayesian pick-the-winner design in a randomized phase II clinical trial.

Chen DT, Huang PY, Lin HY, Chiappori AA, Gabrilovich DI, Haura EB, Antonia SJ, Gray JE.

Oncotarget. 2017 Jul 7;8(51):88376-88385. doi: 10.18632/oncotarget.19088. eCollection 2017 Oct 24.

14.

PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.

Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Moretta F, Mingari MC, Salgarello M, Terzi A, Picece V, Pomari C, Lunardi G, Cavazza A, Rossi G, Moretta L, Bogina G.

Oncotarget. 2017 Oct 4;8(52):90123-90131. doi: 10.18632/oncotarget.21485. eCollection 2017 Oct 27.

15.

Prostaglandin E2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment.

Miao J, Lu X, Hu Y, Piao C, Wu X, Liu X, Huang C, Wang Y, Li D, Liu J.

Oncotarget. 2017 Sep 22;8(52):89802-89810. doi: 10.18632/oncotarget.21155. eCollection 2017 Oct 27.

16.

Myasthenia Gravis Induced by Nivolumab: A Case Report.

Mehta JJ, Maloney E, Srinivasan S, Seitz P, Cannon M.

Cureus. 2017 Sep 20;9(9):e1702. doi: 10.7759/cureus.1702.

17.

Genetic and immune features of resectable malignant brainstem gliomas.

Zhang Y, Pan C, Wang J, Cao J, Liu Y, Wang Y, Zhang L.

Oncotarget. 2017 Jul 28;8(47):82571-82582. doi: 10.18632/oncotarget.19653. eCollection 2017 Oct 10.

18.

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.

David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C.

Oncoimmunology. 2017 Jul 13;6(10):e1349589. doi: 10.1080/2162402X.2017.1349589. eCollection 2017.

19.

Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway.

Shen MJ, Xu LJ, Yang L, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y.

Oncotarget. 2017 Jul 12;8(46):80506-80520. doi: 10.18632/oncotarget.19193. eCollection 2017 Oct 6.

20.

CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.

Wasiuk A, Testa J, Weidlick J, Sisson C, Vitale L, Widger J, Crocker A, Thomas LJ, Goldstein J, Marsh HC, Keler T, He LZ.

J Immunol. 2017 Dec 15;199(12):4110-4123. doi: 10.4049/jimmunol.1700606. Epub 2017 Nov 6.

Supplemental Content

Support Center